7 documents found, page 1 of 1
RIPK3 dampens mitochondrial bioenergetics and lipid droplet dynamics in metabol...
Afonso, Marta B.; Islam, Tawhidul; Magusto, Julie; Amorim, Ricardo; Lenoir, Véronique; Simões, Rui F.; Teixeira, José; Silva, Liana C.Background and Aims: Receptor‐interacting protein kinase 3 (RIPK3) mediates NAFLD progression, but its metabolic function is unclear. Here, we aimed to investigate the role of RIPK3 in modulating mitochondria function, coupled with lipid droplet (LD) architecture in NAFLD. Approach and Results: Functional studies evaluating mitochondria and LD biology were performed in wild‐type (WT) and Ripk3−/− mice fed a cho...
The global NAFLD policy review and preparedness index: are countries ready to a...
Lazarus, Jeffrey V.; Mark, Henry E.; Villota-Rivas, Marcela; Palayew, Adam; Carrieri, Patrizia; Colombo, Massimo; Ekstedt, Mattias; Esmat, GamalBackground & aims: Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent, yet largely underappreciated liver condition which is closely associated with obesity and metabolic disease. Despite affecting an estimated 1 in 4 adults globally, NAFLD is largely absent on national and global health agendas. Methods: We collected data from 102 countries, accounting for 86% of the world population, on NAFLD pol...
Advancing the global public health agenda for NAFLD: a consensus statement
Lazarus, Jeffrey V.; Mark, Henry E.; Anstee, Quentin M.; Arab, Juan Pablo; Batterham, Rachel L.; Castera, Laurent; Cortez-Pinto, Helena; Crespo, JavierNon-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-ranging social and economic implications. It is a multisystem disease and is considered the hepatic component of metabolic syndrome. Unlike other highly prevalent conditions, NAFLD has received little attentio...
European ‘NAFLD Preparedness Index’ — Is Europe ready to meet the challenge of ...
Lazarus, Jeffrey V.; Palayew, Adam; Carrieri, Patrizia; Ekstedt, Mattias; Marchesini, Giulio; Novak, Katja; Ratziu, Vlad; Romero-Gómez, ManuelBackground & aims: Non-alcoholic fatty liver disease (NAFLD), which is closely associated with obesity, metabolic syndrome, and diabetes, is a highly prevalent emerging condition that can be optimally managed through a multidisciplinary patient-centred approach. National preparedness to address NAFLD is essential to ensure that health systems can deliver effective care. We present a NAFLD Preparedness Index for...
Inhibition of receptor-interacting protein kinase 1 improves experimental non-a...
Majdi, Amine; Aoudjehane, Lynda; Ratziu, Vlad; Islam, Tawhidul; Afonso, Marta B; Conti, Filomena; Mestiri, Taïeb; Lagouge, Marie; Foufelle, FabienneIn non-alcoholic fatty liver disease (NAFLD), hepatocytes can undergo necroptosis: a regulated form of necrotic cell death mediated by the receptor-interacting protein kinase (RIPK) 1. Herein, we assessed the potential for RIPK1 and its downstream effector mixed lineage kinase domain-like protein (MLKL) to act as therapeutic targets and markers of activity in NAFLD.
A cross-sectional study of the public health response to non-alcoholic fatty li...
Lazarus, Jeffrey V.; Ekstedt, Mattias; Marchesini, Giulio; Mullen, Jillian; Novak, Katja; Pericàs, Juan M.; Roel, Elena; Romero-Gómez, ManuelBackground & aims: Non-alcoholic fatty liver disease (NAFLD) is a growing public health problem worldwide and has become an important field of biomedical inquiry. We aimed to determine whether European countries have mounted an adequate public health response to NAFLD and non-alcoholic steatohepatitis (NASH). Methods: In 2018 and 2019, NAFLD experts in 29 European countries completed an English-language survey ...
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim an...
Younossi, Zobair M.; Ratziu, Vlad; Loomba, Rohit; Rinella, Mary; Anstee, Quentin M.; Goodman, Zachary; Bedossa, Pierre; Geier, AndreasBackground: Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH. Methods: In this multicentre, randomised, double-blind, placebo-contro...